CellaresCell & Gene Therapy Manufacturing
Cellares automates cell and gene therapy manufacturing to reduce production costs and timelines for developers.
$50MSeries D
Investor undisclosed
A $50M Series D for manufacturing automation in cell/gene therapy signals investors still believe the unit economics problem is solvable—not that the therapy pipeline itself is heating up. Cellares is likely burning this on scaling their platform hardware and hiring ops/engineering to land their first 5-10 anchor customers at scale. If you're building anything in biotech infrastructure (lab automation, supply chain, QA software), this validates that VCs will fund the unsexy-but-critical layer if you can prove you actually reduce COGS or time-to-clinic by a meaningful percentage.